Drugs / Foliglurax
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04275115 | Feb → Apr 2020 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04322227 | Jan → May 2020 | Parkinson disease | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 1 | NCT04175132 | Nov 2019 → Mar 2020 | Parkinson disease | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 1 | NCT04002895 | Jun → Aug 2019 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT02639221 | Jan → Aug 2016 | Parkinson disease | Prexton Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03331848 | Jan 2018 → Feb 2019 | Parkinson disease | Prexton Therapeutics | Withdrawn | No outcome recorded |
| Phase 2 | NCT03162874 | Jul 2017 → Feb 2020 | Parkinson disease | Prexton Therapeutics | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Foliglurax | “Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients” NCT03162874 ↗ |
| Known as | DT-1687 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4089083 ↗ |
| Known as | Lu AF99757 | “Interventional, Open-label, Single-dose Study Investigating the Absorption, Metabolism and Excretion (AME) of Foliglurax (Lu AF99757) Following Oral Dosing of 14C-foliglurax to...” NCT04002895 ↗ |
| Known as | PXT002331 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03162874 ↗ |
| Action | Activate | “Metabotropic glutamate receptor 4 positive allosteric modulator” CHEMBL4089083 ↗ |
| Modality | Small molecule | — CHEMBL4089083 ↗ |
| Route | Oral | “PXT002331 is administered orally as single and multiple doses” NCT02639221 ↗ |
| Target | GRM4 | “Metabotropic glutamate receptor 4 positive allosteric modulator” CHEMBL4089083 ↗ |